The UK has granted marketing authorisation to Venus Remedies Ltd for Cisplatin, a chemotherapy drug used to treat advanced ovarian cancer, testicular cancer, and bladder carcinoma. This development allows the company to offer its affordable cancer drugs to the National Health Service (NHS) in the UK and neighbouring countries. The global market size of Cisplatin was valued at US $394.5 million in 2021, and is expected to grow to US $661.16 million by 2027 at a CAGR of 8.99%, with the UK holding at least 5% of the global market share.
Saransh Chaudhary, President of Global Critical Care at Venus Remedies, shared that the company aims to increase its sales in the UK to approximately 2 million Euros this year. They plan to focus on seven molecules already registered in the UK and augment their sales by 20% year-on-year. Chaudhary also mentioned that Venus Remedies plans to add new molecules in the UK and other European countries, which would help expand its operations and improve sales.
The registration for Cisplatin in the UK could potentially speed up the registration of the oncology product Paclitaxel, which is pending with the MHRA. Venus Remedies is also preparing to apply for marketing authorisation for Bendamustin, a chemotherapy medication used to treat chronic lymphocytic leukaemia, in the UK. The company has already received multiple marketing authorisations from the UK MHRA for a wide range of drugs, including Gemcitabine, Bortezomib, Meropenem, Docetaxel, Carboplatin, and Ceftazidime.
